Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression
Conditions
Interventions
MK-1942
Placebo
Locations
45
United States
University of Alabama at Birmingham - School of Medicine-Psychiatry ( Site 1073)
Birmingham, Alabama, United States
Preferred Research Partners ( Site 1079)
Little Rock, Arkansas, United States
Woodland International Research Group ( Site 1017)
Little Rock, Arkansas, United States
CITrials-Outpatient Facility ( Site 1098)
Bellflower, California, United States
Axiom Research ( Site 1053)
Colton, California, United States
Collaborative Neuroscience Network, LLC. ( Site 1032)
Garden Grove, California, United States
Start Date
May 20, 2021
Primary Completion Date
September 8, 2023
Completion Date
September 8, 2023
Last Updated
September 19, 2024
NCT06731621
NCT04480918
NCT04041479
NCT03320304
NCT06895863
NCT05357040
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions